HIKAL
NSEHikal Limited (SMALL CAP)
Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹244.75
11.16 (4.78%)
High VOLATILITY
As on 10 Jul 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹3.02K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
N/A
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹146.25+67.4%
52W High₹355-31.1%
Current Price
₹244.75
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹195.80
Upper Circuit₹293.70
Reference Price
₹244.75
Investment Checklist
Descending Channel on 1W — target ₹237.41
Falling Wedge on 1W — target ₹282.7
3-day momentum: +12.6% — strong upward pressure
Trend: Price above all key MAs — strong uptrend
RSI at 75.0 — overbought, pullback risk
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Confidence
47%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend
EMA20
217.06
EMA50
205.62
EMA200
220.98
Price Action
MIXED
NEUTRAL
Higher Highs5
Higher Lows6
Lower Highs4
Lower Lows3
Support & Resistance Levels
Resistance (Above)
₹245.61
₹256.15
₹261.00
₹275.75
₹282.70
Support (Below)
₹236.20
₹228.00
₹222.80
₹218.00
₹199.44
Volume Analysis
TrendINCREASING
Change+186.10%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹242.30
3% Risk₹237.41
5% Risk₹232.51
7% Risk (Custom)
₹227.62Technical Levels
1x ATR (Volatility)₹234.21
2x ATR (Swing)₹223.67
3x ATR (Trend)₹213.13
Immediate Support₹236.20
Moving Averages
EMA 9 (Short-term)₹226.77
EMA 20 (Medium-term)₹217.06
EMA 50 (Trend)₹205.62
EMA 200 (Long-term)₹220.98
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Sep '25 |
|---|---|---|---|---|
| Revenue | ₹438.9 Cr | ₹550 Cr | ₹371.3 Cr | ₹316.2 Cr |
| Net Profit | ₹17.2 Cr | ₹50.2 Cr | ₹-22.4 Cr | ₹-34.9 Cr |
| EPS | ₹1.39 | — | ₹-1.82 | ₹-2.83 |
| Operating Profit | ₹75.7 Cr | ₹121.4 Cr | ₹26.1 Cr | ₹9.1 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Hikal Limited | ₹244.75 | +4.78% | — | ₹3.02K Cr small Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 17 Feb 2026 | Interim Dividend - Re 0.20 Per Share | INTERIM_DIVIDEND |
| 02 Sept 2025 | Dividend - Rs 0.80 Per Share | DIVIDEND |
| 07 Feb 2025 | Interim Dividend - Re 0.60 Per Share | INTERIM_DIVIDEND |
| 10 Sept 2024 | Annual General Meeting | AGM |
| 04 Sept 2024 | Dividend - Re 0.60 Per Share | DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for HIKAL
View All
positive
Business Standard - Markets 3d ago
Pharma stocks: Lupin, Torrent hit new peaks; Sun nears summit; here's why
Pharma stock rally: Orchid Pharma, Hikal, Unichem Labs, IOL Chemicals, SPARC, RPG Life Sciences and Acutaas Chemicals surged up to 13% in Wednesday's trade.
ABGSECABSL10BANKABSLAMCABSLBANETFABSLLIQUIDABSLNN50ETABSLPSEACUTAASALIVUSBSLGOLDETFBSLNIFTYBSLSENETFGGSEC10ABSLHEALTHYHIKALIOLCPJFLLIFEJFL-REJGCHEMLUPINMOMENTUMNIFTYQLITYORCHPHARMARPGLIFESAILIFESILVERSOLARASPARCSUVENTECHChemicalsFinancial Services
NEWS
neutral
Business Standard - Markets 44d ago
Hikal consolidated net profit declines 71.31% in the March 2026 quarter
Sales decline 6.00% to Rs 517.00 crore
HIKALHealthcare
positive
CNBC TV18 - Markets 44d ago
Hikal Q4 results muted; sequential recovery driven by crop protection growth
Hikal reported muted Q4 earnings with profit and margins under pressure, though the company saw sequential recovery in revenue and profitability led by stronger crop protection performance and operational improvement.
HIKALPUNJABCHEMChemicalsHealthcare